Protagonist Therapeutics Inc’s filing revealed that its Director WILLIAM D WADDILL acquired Company’s shares for reported $0.22 million on Mar 17 ’25. In the deal valued at $54.78 per share,4,000 shares were bought.
Then, MOLINA ARTURO MD sold 30,514 shares, generating $1,700,850 in total proceeds. Upon selling the shares at $55.74, the Chief Medical Officer now owns 83,892 shares.
Before that, Ali Asif sold 24,903 shares. Protagonist Therapeutics Inc shares valued at $1,462,553 were divested by the Chief Financial Officer at a price of $58.73 per share. As a result of the transaction, Ali Asif now holds 62,821 shares, worth roughly $3.33 million.
Goldman initiated its Protagonist Therapeutics Inc [PTGX] rating to a Neutral in a research note published on December 06, 2024; the price target was $47. A number of analysts have revised their coverage, including BMO Capital Markets’s analysts, who began to cover the stock in early December with a ‘”an Outperform”‘ rating. Wedbush began covering PTGX with “an Outperform” recommendation on November 05, 2024. TD Cowen started covering the stock on September 24, 2024. It rated PTGX as “a Buy”.
Price Performance Review of PTGX
On Monday, Protagonist Therapeutics Inc [NASDAQ:PTGX] saw its stock fall -3.23% to $53.01. Over the last five days, the stock has lost -5.25%. Protagonist Therapeutics Inc shares have risen nearly 37.33% since the year began. Nevertheless, the stocks have risen 75.53% over the past one year. While a 52-week high of $60.60 was reached on 03/12/25, a 52-week low of $24.22 was recorded on 02/25/25. SMA at 50 days reached $40.00, while 200 days put it at $40.41.
Levels Of Support And Resistance For PTGX Stock
The 24-hour chart illustrates a support level at 52.10, which if violated will result in even more drops to 51.18. On the upside, there is a resistance level at 54.09. A further resistance level may holdings at 55.16. The Relative Strength Index (RSI) on the 14-day chart is 66.87, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 8.58, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 29.43%. Stochastics %K at 75.91% indicates the stock is a holding.
How much short interest is there in Protagonist Therapeutics Inc?
A steep rise in short interest was recorded in Protagonist Therapeutics Inc stocks on 2025-02-28, growing by 1.07 million shares to a total of 4.87 million shares. Yahoo Finance data shows the prior-month short interest on 2025-01-31 was 3.79 million shares. There was a rise of 22.03%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on September 09, 2024 when Truist began covering the stock and recommended ‘”a Buy”‘ rating along with a $60 price target.
